Neurogene Inc. (NGNE) stock
NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
$23.10−0.20 (-0.86%)
Close on Nov 17, 2026Market cap $462.26MP/E –Yield –
Neurogene cash
Cash and short-term investments held at the end of each period.
Neurogene's cash was $225.39M at Jun 30, 2026. For fiscal 2025 it was $269.00M, down 13.9% from the year before. Over ten years it grew 21.1% a year on average. The highest annual figure on record is $312.40M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $269.00M | -13.9% |
| FY2024 | Dec 31, 2024 | $312.40M | +58.0% |
| FY2023 | Dec 31, 2023 | $197.67M | +141.0% |
| FY2022 | Dec 31, 2022 | $82.02M | +16.3% |
| FY2021 | Dec 31, 2021 | $70.54M | -63.5% |
| FY2020 | Dec 31, 2020 | $193.43M | +35.2% |
| FY2019 | Dec 31, 2019 | $143.09M | +86.0% |
| FY2018 | Dec 31, 2018 | $76.93M | +47.8% |
| FY2017 | Dec 31, 2017 | $52.03M | +61.1% |
| FY2016 | Dec 31, 2016 | $32.30M | -18.3% |
| FY2015 | Dec 31, 2015 | $39.53M | +165.2% |
| FY2014 | Dec 31, 2014 | $14.91M | +7.8% |
| FY2013 | Dec 31, 2013 | $13.83M | +591.0% |
| FY2012 | Dec 31, 2012 | $2.00M | -78.3% |
| FY2011 | Dec 31, 2011 | $9.24M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $225.39M | -18.0% |
| Q1 FY2026 | Mar 31, 2026 | $243.18M | -17.0% |
| Q4 FY2025 | Dec 31, 2025 | $269.00M | -13.9% |
| Q3 FY2025 | Sep 30, 2025 | $265.41M | +90.5% |
| Q2 FY2025 | Jun 30, 2025 | $274.86M | +78.2% |
| Q1 FY2025 | Mar 31, 2025 | $292.94M | +72.4% |
| Q4 FY2024 | Dec 31, 2024 | $312.40M | +58.0% |
| Q3 FY2024 | Sep 30, 2024 | $139.33M | +41.0% |
| Q2 FY2024 | Jun 30, 2024 | $154.24M | +40.2% |
| Q1 FY2024 | Mar 31, 2024 | $169.87M | +45.8% |
| Q4 FY2023 | Dec 31, 2023 | $197.67M | +141.0% |
| Q3 FY2023 | Sep 30, 2023 | $98.84M | -8.3% |
| Q2 FY2023 | Jun 30, 2023 | $110.00M | -6.3% |
| Q1 FY2023 | Mar 31, 2023 | $116.49M | -9.7% |
| Q4 FY2022 | Dec 31, 2022 | $82.02M | +16.3% |
| Q3 FY2022 | Sep 30, 2022 | $107.76M | -30.8% |
| Q2 FY2022 | Jun 30, 2022 | $117.34M | -28.9% |
| Q1 FY2022 | Mar 31, 2022 | $128.94M | -28.1% |
| Q4 FY2021 | Dec 31, 2021 | $70.54M | -63.5% |
| Q3 FY2021 | Sep 30, 2021 | $155.80M | -22.9% |
| Q2 FY2021 | Jun 30, 2021 | $165.11M | +26.5% |
| Q1 FY2021 | Mar 31, 2021 | $179.27M | +28.1% |
| Q4 FY2020 | Dec 31, 2020 | $193.43M | +35.2% |
| Q3 FY2020 | Sep 30, 2020 | $202.03M | +204.7% |
| Q2 FY2020 | Jun 30, 2020 | $130.47M | +79.5% |
| Q1 FY2020 | Mar 31, 2020 | $139.93M | +88.7% |
| Q4 FY2019 | Dec 31, 2019 | $143.09M | +86.0% |
| Q3 FY2019 | Sep 30, 2019 | $66.31M | -23.5% |
| Q2 FY2019 | Jun 30, 2019 | $72.70M | -26.7% |
| Q1 FY2019 | Mar 31, 2019 | $74.17M | +11.3% |
| Q4 FY2018 | Dec 31, 2018 | $76.93M | +47.8% |
| Q3 FY2018 | Sep 30, 2018 | $86.73M | +84.1% |
| Q2 FY2018 | Jun 30, 2018 | $99.13M | +265.2% |
| Q1 FY2018 | Mar 31, 2018 | $66.61M | +218.5% |
| Q4 FY2017 | Dec 31, 2017 | $52.03M | +61.1% |
| Q3 FY2017 | Sep 30, 2017 | $47.11M | -45.4% |
| Q2 FY2017 | Jun 30, 2017 | $27.15M | – |
| Q1 FY2017 | Mar 31, 2017 | $20.92M | – |
| Q4 FY2016 | Dec 31, 2016 | $32.30M | – |
| Q3 FY2016 | Sep 30, 2016 | $86.23M | – |
See a number that looks wrong?